- Datum18.07.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Altan Cantürk
Moderator
Capricor Therapeutics Inc. Aktie
Verkaufen
Kaufen
Capricor Therapeutics Inc. Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Capricor Therapeutics Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-1,10 %
Intraday
-6,28 %
1 Woche
-40,03 %
1 Monat
-48,12 %
Seit Jahresbeginn
52,99 %
1 Jahr
63,47 %
3 Jahre
34,59 %
5 Jahre
-85,96 %
10 Jahre
Passender Service zu Capricor Therapeutics Inc.
Webinar zu Capricor Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)3,520-23,400
- Jahrestief / Hoch ($)6,070-16,465
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Capricor Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Capricor Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
